Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

North American Expert Review of Rotational Atherectomy.

Sharma SK, Tomey MI, Teirstein PS, Kini AS, Reitman AB, Lee AC, Généreux P, Chambers JW, Grines CL, Himmelstein SI, Thompson CA, Meredith IT, Bhave A, Moses JW.

Circ Cardiovasc Interv. 2019 May;12(5):e007448. doi: 10.1161/CIRCINTERVENTIONS.118.007448.

PMID:
31084239
2.

Phosphoregulation on mitochondria: Integration of cell and organelle responses.

Lucero M, Suarez AE, Chambers JW.

CNS Neurosci Ther. 2019 Jul;25(7):837-858. doi: 10.1111/cns.13141. Epub 2019 Apr 25. Review.

PMID:
31025544
3.

Direct Stenting in Patients Treated with Orbital Atherectomy: An ORBIT II Subanalysis.

Shlofmitz E, Martinsen BJ, Behrens AN, Ali ZA, Lee MS, Puma JA, Shlofmitz RA, Chambers JW.

Cardiovasc Revasc Med. 2019 Jun;20(6):454-460. doi: 10.1016/j.carrev.2019.03.011. Epub 2019 Mar 21.

PMID:
30982659
4.

Sab concentrations indicate chemotherapeutic susceptibility in ovarian cancer cell lines.

Paudel I, Hernandez SM, Portalatin GM, Chambers TP, Chambers JW.

Biochem J. 2018 Nov 15;475(21):3471-3492. doi: 10.1042/BCJ20180603.

PMID:
30322886
5.

Procedural and long-term ischemic outcomes of tight subtotal occlusions treated with orbital atherectomy: An ORBIT II subanalysis.

Lee MS, Shlofmitz RA, Shlofmitz E, Behrens AN, Revtyak G, Martinsen BJ, Chambers JW.

Cardiovasc Revasc Med. 2018 Sep 13. pii: S1553-8389(18)30413-5. doi: 10.1016/j.carrev.2018.09.011. [Epub ahead of print]

PMID:
30243964
6.

Outcomes after atherectomy treatment of severely calcified coronary bifurcation lesions: A single center experience.

Chambers JW, Warner C, Cortez J, Behrens AN, Wrede DT, Martinsen BJ.

Cardiovasc Revasc Med. 2018 Aug 23. pii: S1553-8389(18)30393-2. doi: 10.1016/j.carrev.2018.08.017. [Epub ahead of print]

7.

The clinical evaluation of the CADence device in the acoustic detection of coronary artery disease.

Thomas JL, Ridner M, Cole JH, Chambers JW, Bokhari S, Yannopoulos D, Kern M, Wilson RF, Budoff MJ.

Int J Cardiovasc Imaging. 2018 Dec;34(12):1841-1848. doi: 10.1007/s10554-018-1403-4. Epub 2018 Jun 23.

PMID:
29936668
8.

Orbital atherectomy for the treatment of small (2.5mm) severely calcified coronary lesions: ORBIT II sub-analysis.

Lee MS, Shlofmitz RA, Shlofmitz E, Srivastava PK, Kong J, Grines C, Revytak G, Chambers JW.

Cardiovasc Revasc Med. 2018 Apr;19(3 Pt A):268-272. doi: 10.1016/j.carrev.2017.09.017. Epub 2017 Oct 3.

PMID:
29454531
9.

Impact of age following treatment of severely calcified coronary lesions with the orbital atherectomy system: 3-year follow-up.

Lee MS, Shlofmitz RA, Martinsen BJ, Sethi S, Chambers JW.

Cardiovasc Revasc Med. 2018 Sep;19(6):655-659. doi: 10.1016/j.carrev.2018.01.011. Epub 2018 Jan 31.

PMID:
29452841
10.

ACIST-FFR Study (Assessment of Catheter-Based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement).

Fearon WF, Chambers JW, Seto AH, Sarembock IJ, Raveendran G, Sakarovitch C, Yang L, Desai M, Jeremias A, Price MJ; ACIST-FFR Study Investigators.

Circ Cardiovasc Interv. 2017 Dec;10(12). pii: e005905. doi: 10.1161/CIRCINTERVENTIONS.117.005905.

11.

Orbital atherectomy treatment of severely calcified native coronary lesions in patients with prior coronary artery bypass grafting: Acute and one-year outcomes from the ORBIT II trial.

Lee MS, Anose BM, Martinsen BJ, Lee AC, Shlofmitz RA, Chambers JW.

Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):498-502. doi: 10.1016/j.carrev.2017.10.009. Epub 2017 Nov 5.

PMID:
29117920
12.

Orbital atherectomy for the treatment of severely calcified coronary lesions: evidence, technique, and best practices.

Shlofmitz E, Martinsen BJ, Lee M, Rao SV, Généreux P, Higgins J, Chambers JW, Kirtane AJ, Brilakis ES, Kandzari DE, Sharma SK, Shlofmitz R.

Expert Rev Med Devices. 2017 Nov;14(11):867-879. doi: 10.1080/17434440.2017.1384695. Epub 2017 Oct 4. Review.

PMID:
28945162
13.

Impact of diabetes mellitus on procedural and one year clinical outcomes following treatment of severely calcified coronary lesions with the orbital atherectomy system: A subanalysis of the ORBIT II study.

Lee MS, Martinsen BJ, Lee AC, Behrens AN, Shlofmitz RA, Kim CY, Chambers JW.

Catheter Cardiovasc Interv. 2018 May 1;91(6):1018-1025. doi: 10.1002/ccd.27208. Epub 2017 Jul 22.

PMID:
28733974
14.

Sab is differentially expressed in the brain and affects neuronal activity.

Sodero AO, Rodriguez-Silva M, Salio C, Sassoè-Pognetto M, Chambers JW.

Brain Res. 2017 Sep 1;1670:76-85. doi: 10.1016/j.brainres.2017.06.005. Epub 2017 Jun 9.

PMID:
28606781
15.

Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity.

Chambers TP, Santiesteban L, Gomez D, Chambers JW.

Toxicology. 2017 May 1;382:24-35. doi: 10.1016/j.tox.2017.03.006. Epub 2017 Mar 16.

PMID:
28315715
16.

Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial.

Lee M, Généreux P, Shlofmitz R, Phillipson D, Anose BM, Martinsen BJ, Himmelstein SI, Chambers JW.

Cardiovasc Revasc Med. 2017 Jun;18(4):261-264. doi: 10.1016/j.carrev.2017.01.011. Epub 2017 Jan 23.

PMID:
28162989
17.

Fluorescently labeled circular DNA molecules for DNA topology and topoisomerases.

Gu M, Berrido A, Gonzalez WG, Miksovska J, Chambers JW, Leng F.

Sci Rep. 2016 Oct 31;6:36006. doi: 10.1038/srep36006.

18.

Analysis of Chemotherapeutic Drug Delivery at the Single Cell Level Using 3D-MSI-TOF-SIMS.

Vanbellingen QP, Castellanos A, Rodriguez-Silva M, Paudel I, Chambers JW, Fernandez-Lima FA.

J Am Soc Mass Spectrom. 2016 Dec;27(12):2033-2040. Epub 2016 Aug 31.

19.

ORBIT II sub-analysis: Impact of impaired renal function following treatment of severely calcified coronary lesions with the Orbital Atherectomy System.

Lee MS, Lee AC, Shlofmitz RA, Martinsen BJ, Hargus NJ, Elder MD, Généreux P, Chambers JW.

Catheter Cardiovasc Interv. 2017 Apr;89(5):841-848. doi: 10.1002/ccd.26778. Epub 2016 Aug 27.

PMID:
27567020
20.

Two-year outcomes after treatment of severely calcified coronary lesions with the orbital atherectomy system and the impact of stent types: Insight from the ORBIT II trial.

Généreux P, Bettinger N, Redfors B, Lee AC, Kim CY, Lee MS, Shlofmitz RA, Moses JW, Stone GW, Chambers JW.

Catheter Cardiovasc Interv. 2016 Sep;88(3):369-77. doi: 10.1002/ccd.26554. Epub 2016 Apr 16.

PMID:
27084293
21.

Atherectomy Devices for the Treatment of Calcified Coronary Lesions.

Chambers JW, Behrens AN, Martinsen BJ.

Interv Cardiol Clin. 2016 Apr;5(2):143-151. doi: 10.1016/j.iccl.2015.12.003. Epub 2016 Feb 10. Review.

PMID:
28582200
22.

Gender differences in acute and 30-day outcomes after orbital atherectomy treatment of de novo, severely calcified coronary lesions.

Kim CY, Lee AC, Wiedenbeck TL, Lee MS, Chambers JW.

Catheter Cardiovasc Interv. 2016 Mar;87(4):671-7. doi: 10.1002/ccd.26163. Epub 2015 Sep 2.

PMID:
26331279
23.

Sub-chronic administration of LY294002 sensitizes cervical cancer cells to chemotherapy by enhancing mitochondrial JNK signaling.

Chambers TP, Portalatin GM, Paudel I, Robbins CJ, Chambers JW.

Biochem Biophys Res Commun. 2015 Aug 7;463(4):538-44. doi: 10.1016/j.bbrc.2015.05.075. Epub 2015 May 30.

PMID:
26032505
24.

Orbital Atherectomy for Treating De Novo Severely Calcified Coronary Narrowing (1-Year Results from the Pivotal ORBIT II Trial).

Généreux P, Lee AC, Kim CY, Lee M, Shlofmitz R, Moses JW, Stone GW, Chambers JW.

Am J Cardiol. 2015 Jun 15;115(12):1685-90. doi: 10.1016/j.amjcard.2015.03.009. Epub 2015 Mar 24.

25.

A rapid and sensitive high-throughput screening method to identify compounds targeting protein-nucleic acids interactions.

Alonso N, Guillen R, Chambers JW, Leng F.

Nucleic Acids Res. 2015 Apr 30;43(8):e52. doi: 10.1093/nar/gkv069. Epub 2015 Feb 4.

26.

Real-time decision support to guide percutaneous coronary intervention bleeding avoidance strategies effectively changes practice patterns.

Strauss CE, Porten BR, Chavez IJ, Garberich RF, Chambers JW, Baran KW, Poulose AK, Henry TD.

Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):960-7. doi: 10.1161/CIRCOUTCOMES.114.001275. Epub 2014 Nov 4. Review. No abstract available.

PMID:
25371541
27.

Evaluation of the Diamondback 360 Coronary Orbital Atherectomy System for treating de novo, severely calcified lesions.

Chambers JW, Diage T.

Expert Rev Med Devices. 2014 Sep;11(5):457-66. doi: 10.1586/17434440.2014.929493. Epub 2014 Jun 25. Review.

PMID:
24961517
28.

A trivalent approach for determining in vitro toxicology: Examination of oxime K027.

Prado A, Petroianu GA, Lorke DE, Chambers JW.

J Appl Toxicol. 2015 Feb;35(2):219-27. doi: 10.1002/jat.3013. Epub 2014 May 22.

PMID:
24853289
29.

Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II).

Chambers JW, Feldman RL, Himmelstein SI, Bhatheja R, Villa AE, Strickman NE, Shlofmitz RA, Dulas DD, Arab D, Khanna PK, Lee AC, Ghali MG, Shah RR, Davis TP, Kim CY, Tai Z, Patel KC, Puma JA, Makam P, Bertolet BD, Nseir GY.

JACC Cardiovasc Interv. 2014 May;7(5):510-8. doi: 10.1016/j.jcin.2014.01.158.

30.

A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases.

Feng Y, Chambers JW, Iqbal S, Koenig M, Park H, Cherry L, Hernandez P, Figuera-Losada M, LoGrasso PV.

ACS Chem Biol. 2013 Aug 16;8(8):1747-54. doi: 10.1021/cb3006165. Epub 2013 Jun 10.

31.

Inhibition of JNK mitochondrial localization and signaling is protective against ischemia/reperfusion injury in rats.

Chambers JW, Pachori A, Howard S, Iqbal S, LoGrasso PV.

J Biol Chem. 2013 Feb 8;288(6):4000-11. doi: 10.1074/jbc.M112.406777. Epub 2012 Dec 20.

32.

Blocking c-Jun N-terminal kinase (JNK) translocation to the mitochondria prevents 6-hydroxydopamine-induced toxicity in vitro and in vivo.

Chambers JW, Howard S, LoGrasso PV.

J Biol Chem. 2013 Jan 11;288(2):1079-87. doi: 10.1074/jbc.M112.421354. Epub 2012 Nov 26.

33.

Atmospheric oxygen inhibits growth and differentiation of marrow-derived mouse mesenchymal stem cells via a p53-dependent mechanism: implications for long-term culture expansion.

Boregowda SV, Krishnappa V, Chambers JW, Lograsso PV, Lai WT, Ortiz LA, Phinney DG.

Stem Cells. 2012 May;30(5):975-87. doi: 10.1002/stem.1069.

34.

Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease.

Chambers JW, Pachori A, Howard S, Ganno M, Hansen D Jr, Kamenecka T, Song X, Duckett D, Chen W, Ling YY, Cherry L, Cameron MD, Lin L, Ruiz CH, Lograsso P.

ACS Chem Neurosci. 2011 Apr 20;2(4):198-206.

35.

Selective inhibition of mitochondrial JNK signaling achieved using peptide mimicry of the Sab kinase interacting motif-1 (KIM1).

Chambers JW, Cherry L, Laughlin JD, Figuera-Losada M, Lograsso PV.

ACS Chem Biol. 2011 Aug 19;6(8):808-18. doi: 10.1021/cb200062a. Epub 2011 May 24.

36.

Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation.

Chambers JW, LoGrasso PV.

J Biol Chem. 2011 May 6;286(18):16052-62. doi: 10.1074/jbc.M111.223602. Epub 2011 Mar 16.

37.

Quercetin, a fluorescent bioflavanoid, inhibits Trypanosoma brucei hexokinase 1.

Dodson HC, Lyda TA, Chambers JW, Morris MT, Christensen KA, Morris JC.

Exp Parasitol. 2011 Feb;127(2):423-8. doi: 10.1016/j.exppara.2010.10.011. Epub 2010 Nov 11.

38.

Glutamine metabolism is essential for human cytomegalovirus infection.

Chambers JW, Maguire TG, Alwine JC.

J Virol. 2010 Feb;84(4):1867-73. doi: 10.1128/JVI.02123-09. Epub 2009 Nov 25.

39.

Abnormalities in brain structure and behavior in GSK-3alpha mutant mice.

Kaidanovich-Beilin O, Lipina TV, Takao K, van Eede M, Hattori S, Laliberté C, Khan M, Okamoto K, Chambers JW, Fletcher PJ, MacAulay K, Doble BW, Henkelman M, Miyakawa T, Roder J, Woodgett JR.

Mol Brain. 2009 Nov 19;2:35. doi: 10.1186/1756-6606-2-35.

40.

Effects of 5-HT depletion in the frontal cortex or nucleus accumbens on response inhibition measured in the 5-choice serial reaction time test and on a DRL schedule.

Fletcher PJ, Chambers JW, Rizos Z, Chintoh AF.

Behav Brain Res. 2009 Jul 19;201(1):88-98. doi: 10.1016/j.bbr.2009.01.036. Epub 2009 Feb 6.

PMID:
19428621
41.

Assembly of heterohexameric trypanosome hexokinases reveals that hexokinase 2 is a regulable enzyme.

Chambers JW, Kearns MT, Morris MT, Morris JC.

J Biol Chem. 2008 May 30;283(22):14963-70. doi: 10.1074/jbc.M802124200. Epub 2008 Apr 3.

42.

The anti-trypanosomal agent lonidamine inhibits Trypanosoma brucei hexokinase 1.

Chambers JW, Fowler ML, Morris MT, Morris JC.

Mol Biochem Parasitol. 2008 Apr;158(2):202-7. doi: 10.1016/j.molbiopara.2007.12.013. Epub 2008 Jan 3.

PMID:
18262292
43.

Residues in an ATP binding domain influence sugar binding in a trypanosome hexokinase.

Chambers JW, Morris MT, Smith KS, Morris JC.

Biochem Biophys Res Commun. 2008 Jan 18;365(3):420-5. Epub 2007 Nov 9.

PMID:
17996732
44.

Activity of a second Trypanosoma brucei hexokinase is controlled by an 18-amino-acid C-terminal tail.

Morris MT, DeBruin C, Yang Z, Chambers JW, Smith KS, Morris JC.

Eukaryot Cell. 2006 Dec;5(12):2014-23. Epub 2006 Oct 6.

45.

The challenge of leadership in technology and education.

Chambers JW.

J Am Coll Dent. 2004 Winter;71(4):22-5.

PMID:
15948489
46.

Neonatal ablation of the nigrostriatal dopamine pathway does not influence limb development in rats.

Hebb MO, Lang AE, Fletcher PJ, Chambers JW, Lozano AM.

Exp Neurol. 2002 Oct;177(2):547-56.

PMID:
12429200
47.

Selective destruction of brain serotonin neurons by 5,7-dihydroxytryptamine increases responding for a conditioned reward.

Fletcher PJ, Korth KM, Chambers JW.

Psychopharmacology (Berl). 1999 Dec;147(3):291-9.

PMID:
10639688
49.

Direct in vivo effects of nitric oxide on the coronary circulation.

Chambers JW, Voss GS, Snider JR, Meyer SM, Cartland JL, Wilson RF.

Am J Physiol. 1996 Oct;271(4 Pt 2):H1584-93.

PMID:
8897955
50.

Market competition and growth of hospital staff.

Chambers JW.

Health Aff (Millwood). 1996 Winter;15(4):223-4. No abstract available.

PMID:
8991282

Supplemental Content

Loading ...
Support Center